Nobel Prize
Laureate Dr. Barry
Marshall to
Join Advisory
Board of Xcelerate, Inc.
MAULDIN, SC
-- February 23, 2021 -- InvestorsHub NewsWire
-- Xcelerate, Inc (OTC:
"UDHI") is honored to announce Barry James Marshall AC FRACP FRS FAA
will
join its Advisory
Board, effective immediately. In 2005 Dr. Marshall and his longtime
collaborator Dr. Robin Warren
were awarded
the
Nobel
Prize
in
Physiology
or Medicine for their discovery of
the bacterium Helicobacter
pylori (H.
pylori)
and
its
role in peptic ulcer disease. This
discovery also
established
the
causative
link between Helicobacter
pylori infection
and stomach cancer. Currently
Dr. Marshall serves as Clinical Professor and Director of The
Marshall Centre for Infectious Diseases Research at University of
Western Australia. Additionally,
Dr. Marshall has been involved with the establishment of the
Marshall Laboratory for Biomedical Engineering at Shenzhen
University
"This is truly a
breakthrough
day for Xcelerate,"
said Michael O'Shea, Xcelerate' s CEO. "Adding a
Nobel Prize
researcher
and medical
technology innovator to our Advisory Board will greatly
accelerate
the
transition
to our next phase of business
development while supplying
a tremendous boost
toward our long-term goal of a NASDAQ
listing. Xcelerate is seeking to
acquire innovation at the
patent/engineering level, marry it to early-stage medtech
companies, and supply it in a controlled
clinical care setting where developments will be trialed,
tested,
and
applied.
This
will provide
end-to-end controlled medtech
development resulting in
quicker
product
profitability
and greater
ROI by
fostering engineering, clinical and business developments under one
umbrella."
To interview either
Dr. Marshall or Mr. O'Shea, contact
Justin
Baronoff
561-750-9800;
justin@transmediagroup.com
This press
release may contain forward-looking information within the meaning
of Section 21E of Securities Exchange Act of 1934, as amended (the
"Exchange Act"), including all statements not
statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or officers with respect
to, among other things: (i)
the Company's financing plans; (ii) trends affecting Company's
financial condition or results of operations; (iii) Company's
growth strategy and operating strategy; and (iv) the declaration
and payment of dividends. The words "may," "would," "will,"
"expect," "estimate," "anticipate," "believe," "intend," and
similar expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, beyond the Company's ability
to control, and actual results may differ materially from those
projected in forward-looking statements resulting
from various
factors.
Media Contact: Justin Baronoff
561-750-9800;
justin@transmediagroup.com